B2M
Overview
The B2M (β2-microglobulin) gene plays a crucial role in the function of the major histocompatibility complex (MHC) class I molecules, which are essential for immune system recognition of infected or malignant cells. B2M mutations in B-cell lymphomas, particularly in DLBCL and PMBCL, lead to reduced MHC class I expression, enabling tumor cells to evade immune detection and destruction by cytotoxic T cells.
Relevance tier by entity
| Entity | Tier | Description |
|---|---|---|
 |
1 | high-confidence DLBCL gene |
 |
1 | high-confidence FL gene |
 |
2 | relevance in MCL not firmly established |
Mutation incidence in large patient cohorts (GAMBL reanalysis)
| Entity | source | frequency (%) |
|---|---|---|
| BL | GAMBL genomes+capture | 2.31 |
| BL | Thomas cohort | 2.50 |
| BL | Panea cohort | 3.00 |
| DLBCL | GAMBL genomes | 15.11 |
| DLBCL | Schmitz cohort | 15.53 |
| DLBCL | Reddy cohort | 12.11 |
| DLBCL | Chapuy cohort | 11.97 |
| FL | GAMBL genomes | 8.55 |
| MCL | GAMBL genomes | 1.42 |
Mutation pattern and selective pressure estimates
| Entity | aSHM | Significant selection | dN/dS (missense) | dN/dS (nonsense) |
|---|---|---|---|---|
| BL | No | No | 9.379 | 56.571 |
| DLBCL | No | Yes | 60.843 | 340.788 |
| FL | No | Yes | 54.190 | 326.834 |
[!NOTE] First described in DLBCL in 2011 by Morin RD. First described in FL in 2011 by Morin RD. First described in MCL in 2020 by Pararajalingam P
## B2M Hotspots
| Chromosome | Coordinate (hg19) | ref>alt | HGVSp |
|---|---|---|---|
| chr15 | 45003745 | A>G | M1? |
| chr15 | 45003745 | A>T | M1? |
| chr15 | 45003745 | AGATGTCT>- | NA |
| chr15 | 45003746 | T>A | M1? |
| chr15 | 45003746 | T>C | M1? |
| chr15 | 45003746 | T>G | M1? |
| chr15 | 45003747 | G>A | M1? |
| chr15 | 45003747 | G>C | M1? |
| chr15 | 45003758 | T>A | V5E |
| chr15 | 45003761 | C>A | A6D |
| chr15 | 45003764 | T>C | L7S |
| chr15 | 45003764 | T>G | L7* |
| chr15 | 45003766 | G>C | A8P |
| chr15 | 45003767 | C>A | A8D |
| chr15 | 45003770 | T>A | V9E |
| chr15 | 45003770 | T>G | V9G |
| chr15 | 45003779 | T>A | L12Q |
| chr15 | 45003779 | T>C | L12P |
| chr15 | 45003779 | T>G | L12R |
| chr15 | 45003781 | C>T | L13F |
| chr15 | 45003782 | T>C | L13P |
View coding variants in ProteinPaint hg19 or hg38
View all variants in GenomePaint hg19 or hg38
B2M Expression
References
- Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, Jackman S, Krzywinski M, Scott DW, Trinh DL, Tamura-Wells J, Li S, Firme MR, Rogic S, Griffith M, Chan S, Yakovenko O, Meyer IM, Zhao EY, Smailus D, Moksa M, Chittaranjan S, Rimsza L, Brooks-Wilson A, Spinelli JJ, Ben-Neriah S, Meissner B, Woolcock B, Boyle M, McDonald H, Tam A, Zhao Y, Delaney A, Zeng T, Tse K, Butterfield Y, Birol I, Holt R, Schein J, Horsman DE, Moore R, Jones SJ, Connors JM, Hirst M, Gascoyne RD, Marra MA. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011 Jul 27;476(7360):298-303. doi: 10.1038/nature10351. PMID: 21796119; PMCID: PMC3210554.
Citing
If you use the information or data from this site, please cite
Krysta Coyle, Kostiantyn Dreval, Daniel Hodson and Ryan D. Morin. Audit of B-cell cancer genes. Blood Adv (2025) 9 (8): 2019–2031.
Disclaimer
The content in these pages has been populated, in part, by an automated process. Although we have scrutinized every page to ensure accuracy, errors will inevitably exist. If you find an error please report it as an issue and we will address it.
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms.
